ストックスクリーナーアプリを入手
5.84
7.89%
-0.50
プレマーケット:
5.86
0.02
+0.34%
Verastem Inc (VSTM) 最新ニュース
Gap Down: What analysts say about Verastem Inc stock2025 Historical Comparison & Stock Timing and Entry Methods - baoquankhu1.vn
VSTM: Strong sales, robust clinical progress, and major data updates expected mid-year - TradingView
FY2025 EPS Estimates for Verastem Increased by HC Wainwright - MarketBeat
Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Verastem, Inc. (VSTM) Stock Analysis: Exploring the 164.73% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
HC Wainwright Forecasts Verastem FY2025 Earnings - MarketBeat
Analysts Have Conflicting Sentiments on These Healthcare Companies: Minerva Neurosciences (NERV) and Verastem (VSTM) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), InflaRx (IFRX) and Verastem (VSTM) - The Globe and Mail
Verastem Extends Cash Runway and Highlights 2025 Results - The Globe and Mail
Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results - The Globe and Mail
Verastem Inc (VSTM) CEO Dan Paterson Sells 970 Shares - GuruFocus
HC Wainwright Estimates Verastem FY2030 Earnings - MarketBeat
VSTM: HC Wainwright & Co. Assumes 'Buy' Rating with Price Target of $18.00 | VSTM Stock News - GuruFocus
Verastem Oncology: Preliminary Q4/2025 Revenue and Business Updates; 2026 Priorities for Novel RAS/MAPK Pathway-Driven Cancer Portfolio - marketscreener.com
Verastem Projects $17.5 Million Net Revenue for Q4 2025 - Intellectia AI
Verastem (VSTM) Makes Strides with Innovative Cancer Treatments - GuruFocus
Verastem (NASDAQ:VSTM) Now Covered by HC Wainwright - MarketBeat
B.Riley reiterates Buy rating on Verastem stock, maintains $16 target - Investing.com Nigeria
Verastem stock rating initiated at Buy by H.C. Wainwright with $18 target - Investing.com Canada
B.Riley reiterates Buy rating on Verastem stock, maintains $16 target By Investing.com - Investing.com South Africa
Verastem reports $17.5 million in Q4 revenue for cancer treatment By Investing.com - Investing.com Canada
Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers - ChartMill
RBC Capital Remains a Buy on Verastem (VSTM) - The Globe and Mail
Verastem, Inc. (VSTM): Investor Outlook With A Potential Upside Of 151.56% - DirectorsTalk Interviews
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors - Cantech Letter
ETF Watch: Is Verastem Inc forming a double bottomWeekly Gains Report & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Breakout Zone: What is the Moat Score of Verastem IncJuly 2025 Market Mood & Safe Capital Growth Tips - baoquankhu1.vn
Microvast, Datavault AI, RH, Becton Dickinson, Verastem Shake-Up - TipRanks
Retail Trends: Does Verastem Inc have a competitive edgeJuly 2025 Levels & Risk Controlled Swing Alerts - baoquankhu1.vn
Have Verastem Insiders Been Selling Stock? - simplywall.st
CEO Change: Is Icahn Enterprises LP showing insider buyingJuly 2025 Chart Watch & Accurate Buy Signal Notifications - baoquankhu1.vn
Resistance Check: Does Verastem Inc outperform in volatile markets2025 Market Outlook & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Insider Sell: Dan Paterson Sells Shares of Verastem Inc (VSTM) - GuruFocus
Daniel Calkins Sells 5,039 Shares of Verastem (NASDAQ:VSTM) Stock - MarketBeat
Insider Selling: Verastem (NASDAQ:VSTM) CEO Sells 10,321 Shares of Stock - MarketBeat
EPS Watch: Why Verastem Inc stock is trending among retail tradersTrade Risk Assessment & Reliable Entry Point Alerts - Bộ Nội Vụ
Analysts Are Bullish on These Healthcare Stocks: SOPHiA GENETICS (SOPH), Verastem (VSTM) - The Globe and Mail
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Chartmill
Polar Capital Holdings Plc Increases Stake in Verastem Inc - GuruFocus
Verastem, Inc. (VSTM) Investor Outlook: Biotech Stock With Over 100% Potential Upside - DirectorsTalk Interviews
Can Verastem Inc. stock continue upward trendJuly 2025 Price Swings & Consistent Income Trade Recommendations - Улправда
Is Verastem Inc. stock attractive after correctionMarket Performance Recap & Verified Short-Term Trading Plans - ulpravda.ru
Will Verastem Inc. stock attract more institutional investorsJuly 2025 Outlook & Safe Entry Point Identification - Улправда
Verastem updates oncology strategy in new corporate presentation - TipRanks
RBC Raises Price Target on Verastem to $15 From $14, Keeps Outperform, Speculative Risk - marketscreener.com
Immuneering plummets following phase 2 data of atebimetinib for pancreatic cancer - Seeking Alpha
Verastem (NASDAQ:VSTM) Shares Up 19.3%Should You Buy? - MarketBeat
Verastem shifts focus to KRAS G12D and pancreatic programs - MSN
Verastem Advances with Phase 3 Trial Progress and Product Launch Boosting Prospects - MSN
What's Going On With Verastem Stock Friday?Verastem (NASDAQ:VSTM) - Benzinga
Verastem ends trial of Avmapki Fakzynja combo with Amgen's Lumakras in NSCLC - MSN
Verastem Oncology stock drops after hours after discontinuing a clinical trial in lung cancer - MSN
Verastem stock steady as Mizuho reiterates Outperform rating By Investing.com - Investing.com Canada
Verastem Shifts Focus to KRAS G12D and Pancreatic Programs - TipRanks
Verastem to discontinue Avmapki/Fakzynja combo in KRAS G12C-mutated NSCLC - The Pharma Letter
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):